FBR Adds Senior Analyst to Healthcare Practice

Announces Addition of Dr. Rahul R. Jasuja as Senior Research Analyst

Print
| Source: FBR & Co.

ARLINGTON, Va., Jan. 17, 2017 (GLOBE NEWSWIRE) -- FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank serving the middle market, announced today that Rahul R. Jasuja, Ph.D. has joined the equity research department’s healthcare group as a Senior Vice President.  Dr. Jasuja will be based in the Company’s New York office with a focus on the biotech sector.

“Rahul brings more than twenty years of extensive and relevant experience to our team,” said FBR’s Director of Research and Senior Managing Director, David Hilal.  “His background both within the biotechnology field and in the capital markets give him the unique perspective that our clients are looking for.”   

Dr. Jasuja has covered small and mid cap biotech companies throughout his career, most recently serving as Managing Director, Biotechnology Research at Noble Life Sciences Partners.  He has conducted equity research, due-diligence and consulting for institutional investors and moderated therapeutic and business panels at major investor conferences. Dr. Jasuja received his Ph.D. in Immunology at Tufts Medical School, Boston, and carried out his post-doctoral training at Harvard Medical School, Boston.

FBR & Co. (Nasdaq:FBRC) provides investment banking, merger and acquisition advisory, institutional brokerage, and research services through its subsidiaries FBR Capital Markets & Co. and MLV & Co. FBR focuses capital and financial expertise on the following industry sectors: consumer; energy & natural resources; financial institutions; healthcare; industrials; insurance; real estate; and technology, media & telecom. FBR is headquartered in the Washington, D.C. metropolitan area with offices throughout the United States. For more information, please visit www.fbr.com.

Contacts 
Media and Investors: Linda E. Eddy at 703.312.9715 or leddy@fbr.com